CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 139 enrolled
Drug / intervention
Panobinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00425555
NCT00425555Phase 2Completed
CompareCT.gov

A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Novartis Pharmaceuticals·interventional·Posted Jan 23, 2007·Updated Aug 20, 2021

In Brief

A Phase 2 clinical trial evaluating Panobinostat for Cutaneous T-Cell Lymphoma. Completed, enrolled 139 participants across 42 sites in 12 countries.

Detailed Summary

This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous T-Cell Lymphoma
CountriesArgentina, Australia, Belgium, Canada, Finland, France, Germany, Hungary, Italy, Spain, Switzerland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 23, 2007
Enrollment StartJan 1, 2007
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 19.4 years ago

Interventions

Panobinostatdrug